Nerelimomab

Nerelimomab is a mouse monoclonal antibody acting as a TNF inhibitor.^[1]

References

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors: Azathioprine • Mycophenolic acid pyrimidine synthesis inhibitors: Leflunomide • Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus • Ciclosporin • Pimecrolimus Abetimus • Gusperimus

TNF-α inhibitor	Thalidomide • Lenalidomide

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus • Deforolimus • Everolimus • Temsirolimus • Umirolimus • Zotarolimus

Extracellular

Serum target (noncellular)	Complement component 5 (Eculizumab) • TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) • Interleukin 5 (Mepolizumab) • Immunoglobulin E (Omalizumab) • BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab, Ustekinumab)

Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) • CD4 (Clenoliximab, Keliximab, Zanolimumab) • CD11a (Efalizumab) • CD18 (Erlizumab) • CD20 (Afutuzumab, Rituximab, Ocrelizumab, Pascolizumab) • CD23 (Gomiliximab, Lumiliximab) • CD40 (Teneliximab, Toralizumab) • CD62L/L-selectin (Aselizumab) • CD80 (Galiximab) • CD147/Basigin (Gavilimomab) • CD154 (Ruplizumab) BLyS (Belimumab) • CTLA-4 (Ipilimumab, Tremelimumab) • CAT (Bertilimumab, Lerdelimumab, Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atorolimumab, Cedelizumab, Fontolizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab

-cept (Fusion)

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab immune activation: Ipilimumab • Tremelimumab other: Bertilimumab • Zanolimumab

Mouse ("-limo-")	Afelimomab • Elsilimomab • Faralimomab • Gavilimomab • Inolimomab • Maslimomab • Nerelimomab • Odulimomab • Telimomab aritox • Vepalimomab • Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab • Apolizumab • Benralizumab^† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140^† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • Olokizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab • Fanolesomab^‡ • Lemalesomab • Sulesomab

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)